News Article

Acacia nixes £150M IPO as London wobbles; Spirogen team reforms to found ADC biotech
Date: Oct 22, 2015
Author: Nick Paul Taylor
Source: Fierce Biotech ( click here to go to the source)

Featured firm in this article: Acacia Biosciences Inc of Richmond, CA



Welcome to the latest edition of our weekly EuroBiotech Report. The downturn in the IPO market in London claimed its biggest biopharma casualty to date this week when Acacia Pharma postponed its planned £150 million ($231 million) listing. Acacia's decision to hit pause on its plans comes shortly after fellow British biopharma Shield Therapeutics backed away from its own £110 million IPO.